康柏西普不同方案治疗糖尿病黄斑水肿的疗效比较  

Comparison of Efficacy of Different Regimens of Conbercept in the Treatment of Macular Edema in Diabetes

作　　者：汪彬 屈晓勇 欧阳君[1] WANG Bin;QU Xiaoyong;OUYANG Jun(Jiu Jiang NO.1 People's Hospital,Jiujiang Jiangxi 332000,China.)

机构地区：[1]九江市第一人民医院,江西九江332000

出　　处：《药品评价》2022年第13期815-818,共4页Drug Evaluation

基　　金：江西省卫生健康委科技计划项目(20204220)。

摘　　要：目的:比较采用单次注射后改用按需治疗方案(1+PRN)和连续三次每月注射后改用按需方案(3+PRN)康柏西普对于糖尿病黄斑水肿的治疗效果。方法:回顾性分析九江市第一人民医院2019年1月至2019年12月收诊的康柏西普1+PRN治疗的患者37例37眼,以及康柏西普3+PRN治疗的患者40例40眼,患者均为糖尿病性黄斑水肿,观察不同方案康柏西普治疗患者的最佳矫正视力(BCVA)、中心凹视网膜厚度(CMT)以及黄斑区渗漏的变化。结果:与治疗前相比,两组患者治疗后的BCVA均提升,CMT厚度均降低,黄斑区渗漏的范围均缩小,在治疗1月、3月、6月、12月等节点均有显著改善,均差异有统计学意义(均P<0.05);但多个节点进行组间比较,两组BCVA、CMT、黄斑区渗漏的范围比较均差异无统计学意义(P>0.05)。3+PRN组注射频次为(4.51±1.13)次,不良反应例次为(3.04±0.64)次;1+PRN组患者注射频次(3.14±0.87)次,不良反应例次为(1.77±0.47)次。两组间比较,差异有统计学意义(P<0.05)。结论:康柏西普1+PRN和3+PRN的疗法均能对糖尿病黄斑水肿患者起到改善效果,但1+PRN疗法注射药物次数较少,对患者造成的经济压力更小,并且较少的注射次数对眼部刺激较小,安全性较高。Objective:To compare the therapeutic effects of compatriot in the treatment of diabetic macular edema,which adopted the Pro Re Nata regimen after single injection (1+PRN) and the Pro Re Nata regimen after three consecutive monthly injections (3+PRN).Methods:From January 2019 to December 2019,37 patients (37 eyes) treated with conbercept 1+PRN and 40 patients (40 eyes) treated with conbercept 3+PRN admitted to Jiu Jiang NO.1 People’s Hospital were retrospectively analyzed.All patients were diabetic macular edema,and the changes of BCVA,CMT and macular leakage in patients treated with different regimens of conbercept were observed.Results:Compared with before treatment,the BCVA of the two groups of patients after treatment was increased,the CMT thickness was decreased,and the scope of macular leakage was reduced.The comparison was statistically significant (P0.05).For the frequency of drug injection in the two groups,the patients in the 3+PRN group had an average injection of (4.51±1.13) times,and the number of adverse reactions was (3.04±0.64) times,while the average injection frequency of the patients in the 1+PRN group was (3.14±0.87) times,and the adverse reactions were (1.77±0.47).The difference between groups was statistically significant (P<0.05).Conclusion:Conbercept 1+PRN and 3+PRN therapy can improve the patients with diabetic macular edema,but after 1+PRN therapy,the patients need to inject less frequently,which causes more economic pressure.It is small and less irritating to the eye due to fewer injections,and its safety during treatment is higher.

关 键 词：糖尿病视网膜病变 临床方案 1+PRN 3+PRN 康柏西普 黄斑水肿 视力 

分 类 号：R587.2[医药卫生—内分泌] R774.5[医药卫生—内科学]